- Home
- JFU vs LPCN Comparison
JFU vs LPCN Comparison
Compare JFU & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- LPCN
- Stock Information
- Founded
- JFU 2006
- LPCN 1997
- Country
- JFU China
- LPCN United States
- Employees
- JFU N/A
- LPCN N/A
- Industry
- JFU Finance: Consumer Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- LPCN Health Care
- Exchange
- JFU Nasdaq
- LPCN Nasdaq
- Market Cap
- JFU 17.1M
- LPCN 16.1M
- IPO Year
- JFU 2019
- LPCN N/A
- Fundamental
- Price
- JFU $1.40
- LPCN $3.29
- Analyst Decision
- JFU
- LPCN Strong Buy
- Analyst Count
- JFU 0
- LPCN 2
- Target Price
- JFU N/A
- LPCN $9.00
- AVG Volume (30 Days)
- JFU 2.9K
- LPCN 59.4K
- Earning Date
- JFU 01-01-0001
- LPCN 08-07-2025
- Dividend Yield
- JFU N/A
- LPCN N/A
- EPS Growth
- JFU N/A
- LPCN N/A
- EPS
- JFU 0.09
- LPCN N/A
- Revenue
- JFU $40,614,155.00
- LPCN $3,674,834.00
- Revenue This Year
- JFU N/A
- LPCN N/A
- Revenue Next Year
- JFU N/A
- LPCN N/A
- P/E Ratio
- JFU $15.08
- LPCN N/A
- Revenue Growth
- JFU N/A
- LPCN N/A
- 52 Week Low
- JFU $1.01
- LPCN $2.68
- 52 Week High
- JFU $3.60
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- JFU 50.23
- LPCN 51.52
- Support Level
- JFU $1.36
- LPCN $3.13
- Resistance Level
- JFU $1.48
- LPCN $3.53
- Average True Range (ATR)
- JFU 0.07
- LPCN 0.24
- MACD
- JFU -0.01
- LPCN 0.01
- Stochastic Oscillator
- JFU 21.13
- LPCN 48.33
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.